Methylbenzethonium chloride (CAS 25155-18-4)
QUICK LINKS
Methylbenzethonium chloride is a synthetic quaternary ammonium compound that has garnered attention in various research fields for its antimicrobial properties. In studies not related to its clinical use, it serves as a model compound to explore the mechanisms of action of quaternary ammonium salts on bacterial membranes. Researchers utilize methylbenzethonium chloride to understand the biocidal activity of similar compounds, examining how they interact with lipid bilayers and disrupt cellular processes. It is also employed in the study of microbial resistance mechanisms, providing insights into how microbes adapt to and survive in the presence of membrane-targeting agents. In environmental science, the compound is investigated for its behavior in water treatment processes and its potential impact on ecosystems. Methylbenzethonium chloride′s efficacy in reducing microbial load on surfaces makes it a subject of interest in the development of new disinfection strategies and materials, particularly in the context of preventing biofilm formation.
Methylbenzethonium chloride (CAS 25155-18-4) References
- Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (Aminosidine) and gentamicin. | Grogl, M., et al. 1999. J Parasitol. 85: 354-9. PMID: 10219319
- Benzethonium chloride: a novel anticancer agent identified by using a cell-based small-molecule screen. | Yip, KW., et al. 2006. Clin Cancer Res. 12: 5557-69. PMID: 17000693
- Leishmania major: in vitro and in vivo anti-leishmanial activity of paromomycin ointment (Leshcutan) combined with the immunomodulator Imiquimod. | El-On, J., et al. 2007. Exp Parasitol. 116: 156-62. PMID: 17306255
- Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials. | Kim, DH., et al. 2009. PLoS Negl Trop Dis. 3: e381. PMID: 19221595
- Interventions for American cutaneous and mucocutaneous leishmaniasis. | González, U., et al. 2009. Cochrane Database Syst Rev. CD004834. PMID: 19370612
- New World cutaneous leishmaniasis: updated review of current and future diagnosis and treatment. | Mitropoulos, P., et al. 2010. J Am Acad Dermatol. 63: 309-22. PMID: 20303613
- Identification of specific pluripotent stem cell death--inducing small molecules by chemical screening. | Conesa, C., et al. 2012. Stem Cell Rev Rep. 8: 116-27. PMID: 21617963
- High-throughput screening of a collection of known pharmacologically active small compounds for identification of Candida albicans biofilm inhibitors. | Siles, SA., et al. 2013. Antimicrob Agents Chemother. 57: 3681-7. PMID: 23689719
- Antimicrobial and Antibiofilm Activity of Synergistic Combinations of a Commercially Available Small Compound Library With Colistin Against Pseudomonas aeruginosa. | Torres, NS., et al. 2018. Front Microbiol. 9: 2541. PMID: 30410476
- Identification of putative drugs for gastric adenocarcinoma utilizing differentially expressed genes and connectivity map. | Chen, ZX., et al. 2019. Mol Med Rep. 19: 1004-1015. PMID: 30569111
- Comparison between cutaneous leishmaniasis patients with facial and non-facial lesions. | Yedidia Moser, R., et al. 2021. Int J Dermatol. 60: 1109-1113. PMID: 33846973
- Topical treatment of New and Old World cutaneous leishmaniasis in experimental animals. | el-On, J. and Hamburger, AD. 1987. Trans R Soc Trop Med Hyg. 81: 734-7. PMID: 3449988
- An in vitro model for assessing the toxicity of pesticides in beeswax on honey bee larvae. | Kast, C. and Kilchenmann, V. 2022. Chemosphere. 287: 132214. PMID: 34826914
- Assessment of FDA-approved drugs against Strongyloides ratti in vitro and in vivo to identify potentially active drugs against strongyloidiasis. | Keiser, J. and Häberli, C. 2021. Parasit Vectors. 14: 615. PMID: 34949209
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Methylbenzethonium chloride, 10 g | sc-280989 | 10 g | $338.00 |